Piramal Pharma Limited Announces Results for Q3 and 9M FY25
Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Months (9M) ended 31st December 2024. https://mma.prnewswire.com/media/1855206/4913155/Piramal_Pharma_Limited_Logo.jpg Consolidated Financial Highlights(in Cr. or as stated)Particulars Q3FY25 Q3FY24 YoY 9MFY25 9MFY24 YoY Growth GrowthRevenue from Operations 2,204 1,959 13% […]